Tumor models in drug development

Random House College Dictionary, 1975 Schabel FMJr: Animal models as predictive systems. In: Cancer Chemotherapy — Fundamental Concepts and Recent Advances (19th Annual Clinical Conference on Cancer, The University of Texas MD Anderson Hospital and Tumor Institute, Houston, 1974). Year Book Medical Publishers, Chicago, 1975, pp 323–355 Zubrod CG, Schepartz S, Leiter J, Endicott KM, Carrese LM, Baker CG: The chemotherapy program of the National Cancer Institute: History, analysis, and plans. Cancer Chemother Rep 50(7): 349–540, 1966 Burchenal JH: The historical development of cancer chemotherapy. In: Berkarda B, Karrer K, Mathé G (eds) Antineoplastic Chemotherapy. Thieme-Stratton Inc, New York, 1984, pp 3–15 Pratt WB, Ruddon RW: The Anticancer Drugs. Oxford University Press, 1979, pp 12–19 Zubrod CG: Origins and development of chemotherapy research at the National Cancer Institute. Cancer Treat Rep 68(1): 9–19, 1984 Schoenberg BS, Schoenberg DG: Of mice and men, of triumph and tragedy, of murine models of malignant disease. Surg Gyn Obstr 141: 933–937, 1975 Sugiura K: Tumor transplantation. In: Gay WI (ed) Methods of Animal Experimentation. Academic Press, New York, 1965, pp 171–222 Zubrod CG: Historic milestone in curative chemotherapy. Semin Oncol 6(4): 490–505, 1979 Gilman A: The initial clinical trial of nitrogen mustard. Am J Surg 105: 574–578, 1963 Goldin A, Serpick AA, Mantel N: A commentary, experimental screening procedures and clinical predictability value. Cancer Chemother Rep 50(4): 173–218, 1966 Gellhorn A, Hirschberg E: Investigations of diverse systems for cancer chemotherapy screening. Cancer Res Suppl 3: 125, 1955 Carter S: Anticancer drug development progress: A comparison of approaches in the United States, the Soviet Union, Japan, and Western Europe. Natl Cancer Inst Monogr 40: 31–42, 1974 Goldin A, Venditti JM, Muggia FM, Rozencweig M, DeVita VT: New animal models in cancer chemotherapy. In: Fox BW (ed) Advances in Medical Oncology, Research and Education. Vol 5. Basis for Cancer Therapy 1. Pergamon Press, New York, 1979, pp 113–122 Corbett TH, Valeriote FA, Baker LH: Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs 5: 3–20, 1987 Trader MW, Harrison SDJr, Laster WRJr, Griswold DPJr: Cross-resistance and collateral sensitivity of drug-resistant P388 and L1210 leukemias to flavone acetic acid (FAA, NSC 347512) in vivo (Abstr). Proc AACR 28: 312, 1987 Wilkoff LJ, Dulmadge EA: Sensitivity of proliferating cultured murine pancreatic tumor cells to selected antitumor agents. J Natl Cancer Inst 77(5): 1163–1169, 1986 Schabel FMJr, Skipper HE, Fortner JG, Thomson JR, Laster WRJr, Moore JH, Kelley CA, Farnell DR: Experimental evaluation of potential anticancer agents. II. Studies on the growth characteristics, metastases, and drug response of hamster neoplasms of diverse ‘sites of origin’. Cancer Res 21(6): 235–339, 1961 Fortner JG, Mahy AG, Schrodt GR: Transplantable tumors of the Syrian golden hamster. Part I. Tumors of the alimentary tract, endocrine glands and melanomas. Cancer Res 21(6): 161–198, 1961 Fortner JG, Mahy AG, Cotran RS: Transplantable tumors of the Syrian golden hamster. Part II. Tumors of the hematopoietic tissues, genitourinary organs, mammary glands and sarcomas. Cancer Res 21(6): 199–234, 1961 Badiner GJ, Hamilton RD, Li LH, Bhuyan BK: Drug sensitivity of ten human tumor cell lines compared to mouse leukemia (L1210) cells. Invest New Drugs 5: 219–229, 1987 Phillips RM, Bibby MC, Double JA: A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst 82(18): 1457–1468, 1990 Simpson-Herren L, Noker PE, Wagoner SD: Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother Pharmacol 22: 131–136, 1988 Jain RK: Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6: 559–593, 1987 Corbett TH: A selective two-tumor soft agar assay for drug discovery (Abstract). Proc AACR 25: 325, 1984 LoRusso PM, Biernat L, Mandesir JM, Gros P, Corbett T: Antitumor efficacy of SR95325B against murine tumor models (Abstract). Proc AACR 32: 406, 1991 Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461–463, 1977 Shoemaker RH: New approaches to antitumor drug screening: The human tumor colony forming assay. Cancer Treat Rep 70(1): 9–12, 1986 Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589–601, 1988 Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14): 1088–1092, 1989 Steel GG, Peckham MJ: Human tumor xenografts: A critical appraisal. Br J Cancer 41: 133–141, 1980 Mattern J, Bak M, Hahn EW, Volm M: Human tumor xenografts as model for drug testing. Cancer Metastasis Rev 7: 263–284, 1988 Fujita F, Fujita M, Taguchi T, Shimozuma K, Sakamoto Y, Kimoto Y, Hirai T: Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice. Int J Cancer 43: 637–644, 1989